Carvajal syndrome is a rare inherited condition that affects the heart, skin, and hair. It happens when a change (variant) in a gene called DSP (desmoplakin) weakens the “buttons” (desmosomes) that hold heart and skin cells tightly together. Because these cell-to-cell connections are weak, the heart muscle—especially the left ventricle—can become stretched, scarred, and irritable, leading to a form of left-dominant arrhythmogenic cardiomyopathy and dilated cardiomyopathy with dangerous heart rhythms. On the skin, children usually develop thick, cracked skin on the palms and soles (palmoplantar keratoderma) in the first year of life, and woolly, tightly curled hair from birth. The condition was first described in 1998 as a recessive desmoplakin-related cardiocutaneous syndrome and is now known to include both recessive and dominant forms. PMC+4orpha.net+4MedlinePlus+4

Carvajal syndrome is a very rare, inherited “cardio-cutaneous” condition. “Cardio” means it affects the heart; “cutaneous” means it also affects the skin and hair. Most people have three main features: woolly (curly, tightly coiled) hair from birth, thick skin on the palms and soles (palmoplantar keratoderma) that often cracks, and a heart muscle disease that usually involves the left ventricle and can cause irregular heartbeats, fainting, heart-failure symptoms, or sudden cardiac arrest. The usual cause is a harmful change (mutation) in the desmoplakin (DSP) gene. Desmoplakin is a “glue” protein inside desmosomes—the spot-welds that hold heart and skin cells together. When desmoplakin is faulty, the heart muscle can scar and become weak or irritable, and the skin barrier becomes thick or fragile. Carvajal is closely related to Naxos disease (plakoglobin gene), but Carvajal most often targets the left ventricle. heart.bmj.com+3PMC+3PMC+3

Desmoplakin is a key structural protein in desmosomes—tiny rivets that lock cells together and connect them to the inner “cables” (intermediate filaments). Variants that truncate or disrupt desmoplakin reduce the tissue’s mechanical strength. In the heart, repeated mechanical stress then promotes injury, inflammation, scarring (fibrosis), and electrical instability; in the skin and hair follicles, it causes fragility that shows up as keratoderma and woolly hair. MedlinePlus+1

 In many people with DSP variants, scarring is more pronounced in the left ventricle, creating a pattern called left-dominant arrhythmogenic cardiomyopathy (LDAC)—sometimes called “desmoplakin cardiomyopathy.” This differs from classic ARVC (right-sided), and recognizing the left-sided bias avoids misdiagnosis as plain DCM or myocarditis. PMC+2PMC+2

Other names

Carvajal syndrome is also called:

• Keratoderma with woolly hair, type II (the “type II” form in the keratoderma-with-woolly-hair family, with left-ventricular DCM rather than ARVC). MedlinePlus

• Naxos disease variant (Carvajal variant), highlighting its overlap with Naxos disease but with DSP involvement and left-ventricular predominance. NCBI+1

• Desmoplakin cardiomyopathy (a broader term used when heart features dominate, with or without skin/hair signs). PMC

• Arrhythmogenic left ventricular cardiomyopathy (ALVC) with woolly hair and PPK (descriptive clinical label). heartrhythmcasereports.com

Types

1. Classic autosomal recessive Carvajal syndrome. Children present with woolly hair at birth, palmoplantar keratoderma in infancy, and progressive left-dominant arrhythmogenic cardiomyopathy in later childhood/adolescence. Caused by biallelic DSP variants, often truncating. orpha.net+1

2. Autosomal dominant “Carvajal-like”/DSP cardiomyopathy. Some families carry single (heterozygous) DSP variants with a spectrum from isolated cardiomyopathy to the full cardiocutaneous triad. Truncating variants often track with aggressive left-sided disease and arrhythmias. PMC+1

3. Cardiocutaneous overlap phenotypes. People may show variable mixes: woolly/curly hair, palmoplantar keratoderma, dental anomalies (less common), and left-dominant myocarditis-like flares on CMR. PMC+1

4. Related keratoderma-with-woolly-hair spectrum. Type I (Naxos disease; often JUP gene) tends to ARVC (right-sided), while type II (Carvajal/DSP) tends to left-sided DCM. Type III and IV have similar hair/skin findings but different cardiac risks. MedlinePlus+1

Causes

Because Carvajal syndrome is genetic, “causes” mainly mean the underlying gene variants and factors that modulate how the disease appears. Each item is explained as a contributor or trigger, with citations across the list.

1. Biallelic (recessive) truncating variants in DSP that remove key desmoplakin domains—classic Carvajal mechanism. PMC+1

2. Heterozygous (dominant) DSP truncating variants—can produce severe left-dominant arrhythmogenic cardiomyopathy even without full skin triad. Oxford Academic

3. Missense DSP variants—some change protein folding or filament binding and produce variable cardiocutaneous phenotypes. PubMed

4. Variant location within DSP—certain regions carry higher arrhythmic risk (genotype–phenotype correlation). AHA Journals

5. Founder effects in some families/regions—shared ancestral variants raise local prevalence. AHA Journals

6. Desmosome dysfunction as a class effect—DSP loss impairs cell adhesion and mechanical integrity in heart and skin. MedlinePlus

7. Left-ventricular mechanical stress—stresses vulnerable tissue, promoting injury and scar in DSP disease. PMC

8. High-intensity/endurance exercise—accelerates onset, increases penetrance, and raises arrhythmic risk in desmosomal disease. ScienceDirect+2PMC+2

9. Inflammatory “hot phases” (myocarditis-like episodes) seen on CMR—can worsen scarring and symptoms. BioMed Central

10. Arrhythmia-induced cardiomyopathy loop—frequent ventricular arrhythmias further depress function. (Mechanistic inference in ACM reviews.) AHA Journals

11. Modifier genes in other desmosomal proteins (e.g., JUP, PKP2) may influence severity in families. Oxford Academic

12. Puberty-related growth and hormonal shifts—periods of rapid growth can unmask cardiomyopathy in genetic carriers (described across ACM cohorts). heartrhythmjournal.com

13. Viral myocarditis as a trigger—intercurrent myocarditis may amplify fibrosis in genetically susceptible myocardium. BioMed Central

14. Pregnancy/physiologic load—added volume/pressure load can unmask symptoms in DSP cardiomyopathy (reported in ACM practice). AHA Journals

15. Electrolyte stress (fever, dehydration)—can lower arrhythmia threshold in cardiomyopathies. (General ACM/arrhythmia risk principles.) AHA Journals

16. Certain drugs that stress myocardium (e.g., stimulant misuse)—may precipitate arrhythmias in vulnerable hearts. (General ACM guidance.) AHA Journals

17. Consanguinity—raises chance of inheriting two DSP variants in recessive forms. orpha.net

18. Aging-related cumulative stress—scarring and LV dysfunction can progress over time even with moderate activity. heartrhythmjournal.com

19. Dietary/illness-related low potassium or magnesium—nonspecific arrhythmia triggers that aggravate genetic arrhythmia risk. (Arrhythmia care standards.) AHA Journals

20. Diagnostic delay/mislabeling as isolated DCM—late recognition postpones protective strategies, indirectly worsening outcomes. PMC

Symptoms

1. Woolly, tightly curled hair from birth. Often coarse, sometimes sparse. Harmless itself but a clue to the syndrome. MedlinePlus+1

2. Thick, cracked skin on palms and soles (palmoplantar keratoderma) by infancy/early childhood; can fissure and be painful. orpha.net

3. Early fatigue and reduced exercise capacity as the left ventricle weakens. heartrhythmcasereports.com

4. Shortness of breath on exertion due to dilated cardiomyopathy. heartrhythmcasereports.com

5. Palpitations (fast or pounding heartbeat) reflecting ventricular ectopy or tachycardia. AHA Journals

6. Fainting (syncope) or near-syncope during arrhythmias. AHA Journals

7. Chest pain, sometimes during “hot phases” that mimic myocarditis. BioMed Central

8. Swelling of legs/ankles and fluid retention when heart failure develops. AHA Journals

9. Orthopnea (breathlessness lying flat) and nighttime breathlessness in advanced LV failure. AHA Journals

10. Reduced growth/poor weight gain in symptomatic children with significant heart failure. heartrhythmjournal.com

11. Skin fissures and infections at pressure points of hands/feet due to keratoderma. orpha.net

12. Hair fragility and breakage with persistent “woolly” texture. MedlinePlus

13. Exercise intolerance or dizziness during sports, especially endurance activity. ScienceDirect

14. Family history of sudden cardiac death, ICD, heart failure, or similar hair/skin signs—an important symptom-equivalent clue. AHA Journals

15. Emotional stress-triggered palpitations—nonspecific, but often reported in arrhythmia disorders. AHA Journals

Diagnostic tests

Physical exam

1. General inspection. Look for woolly hair and palmoplantar keratoderma; together with cardiac symptoms, this points strongly to Carvajal syndrome. orpha.net

2. Skin exam of palms/soles. Striate or focal thickening with fissures supports a desmoplakin cardiocutaneous phenotype. Medical Journals

3. Vital signs and heart failure signs. Tachycardia, low blood pressure, edema, and crackles may indicate decompensation. AHA Journals

4. Cardiac auscultation. A soft S3, murmurs of functional MR, or gallops can accompany dilated LV failure. AHA Journals

5. Family history mapping. Document relatives with woolly hair/PPK or arrhythmic cardiomyopathy to guide genetic testing. AHA Journals

Manual / bedside tests

6. Orthostatic vitals and exertional walk test. Simple ways to uncover exertional symptoms and low reserve. AHA Journals

7. Six-minute walk test. Tracks functional capacity and response to therapy over time. AHA Journals

8. Skin scraping/dermatology bedside evaluation. Confirms hyperkeratosis pattern and rules out acquired keratodermas. orpha.net

9. Bedside rhythm monitoring (telemetry). Detects PVC burden or runs of VT during admission. AHA Journals

10. Blood pressure/volume assessment including JVP. Helps stage heart failure and guide diuresis. AHA Journals

Laboratory & pathology

11. Cardiac biomarkers (troponin, BNP/NT-proBNP). Troponin may rise during inflammatory “hot phases”; BNP tracks heart failure severity. BioMed Central

12. Comprehensive metabolic panel including electrolytes (K⁺, Mg²⁺). Abnormalities can aggravate arrhythmias and should be corrected. AHA Journals

13. Genetic testing panel including DSP. Confirms the diagnosis, refines risk, and enables cascade testing of relatives. PubMed

14. Targeted family testing for the known DSP variant. Clarifies who needs cardiac surveillance and exercise limits. AHA Journals

15. Endomyocardial biopsy (selected cases). May show fibrofatty replacement or fibrosis but is often replaced by CMR for non-invasive tissue characterization. AHA Journals

Electrodiagnostic

16. 12-lead ECG. Nonspecific but may show low voltages, T-wave inversions (often lateral in DSP-LDAC), or ventricular ectopy. PMC

17. Ambulatory monitoring (Holter/event recorder). Quantifies PVCs and captures nonsustained/sustained VT to guide ICD decisions. AHA Journals

18. Signal-averaged ECG (selected). Can detect late potentials in arrhythmogenic cardiomyopathy, though use varies. AHA Journals

19. Exercise treadmill test (carefully supervised). May provoke diagnostic arrhythmias but must be used judiciously in ACM. PMC

Imaging

20. Transthoracic echocardiogram. First-line to show dilated LV, reduced ejection fraction, regional wall motion abnormalities, and functional MR. heartrhythmcasereports.com

21. Cardiac magnetic resonance (CMR) with LGE and T1/T2 mapping. The key test for DSP disease: detects subepicardial ring-like scar, edema during “hot phases,” and precise LV scar burden for risk stratification. heartrhythmcasereports.com

22. Cardiac MRI in pediatric and young patients. Helps differentiate myocarditis-like flares from genetic scar and supports earlier diagnosis. heartrhythmjournal.com

23. Coronary CT angiography (selected adults). Excludes ischemic disease when presentation is atypical. AHA Journals

24. Cardiac CT/CMR for fibrosis quantification over time. Tracks progression and informs ICD decisions alongside clinical data. AHA Journals

25. Chest radiograph. Low-yield but may show cardiomegaly in advanced LV dilation. AHA Journals

Non-pharmacological treatments (therapies & others)

(Each item: ~150 words: description, purpose, mechanism—kept concise while still simple. Evidence is mainly extrapolated from arrhythmogenic cardiomyopathy [ACM] and DSP-CM guidelines and reviews.)

1) Genetic counseling and cascade testing — Description: Meet a genetics-trained clinician to explain the DSP result, inheritance (often recessive in classic Carvajal; sometimes dominant), and risks for relatives. Purpose: Identify at-risk family members early; plan screening and lifestyle changes. Mechanism: Testing first-degree relatives with targeted DSP analysis plus ECG/CMR finds silent disease; early care reduces arrhythmic events. PMC+1

2) Exercise restriction (dose-right activity) — Description: Avoid high-intensity endurance sports and sustained vigorous activity; prefer light-to-moderate, symptom-limited movement approved by your cardiologist. Purpose: Lower arrhythmia risk and slow scar formation. Mechanism: Reduces mechanical strain and catecholamine surges that trigger ventricular arrhythmias in desmosomal disease. heart.bmj.com

3) Personalized emergency (action) plan — Description: Written plan for palpitations, syncope, chest pain; includes who to call and when to go to hospital. Purpose: Speedy response to dangerous rhythms or hot-phase episodes. Mechanism: Early evaluation with ECG/troponin and rhythm monitoring prevents delay in treating sustained VT or myocarditis-like flares. PMC

4) ICD candidacy assessment — Description: Heart-rhythm team evaluates your lifetime risk for sudden death using symptoms, CMR scar, VT burden, and history. Purpose: Decide on implantable cardioverter-defibrillator (ICD) for prevention. Mechanism: ICD stops life-threatening fast rhythms by rapid pacing or shock. (The procedure itself is surgical; the decision & programming are non-drug measures.) AHA Journals

5) Structured heart-failure self-care — Description: Daily weights, salt awareness, fluid targets, sleep, vaccines, and early call thresholds for swelling or breathlessness. Purpose: Prevent decompensation and hospital stays. Mechanism: Small daily actions balance fluid and blood pressure, protecting a vulnerable ventricle. AHA Journals

6) Cardiac rehabilitation (low-intensity track) — Description: Supervised, gentle programs focusing on safe activity, breathing, and education. Purpose: Improve stamina without arrhythmia triggers. Mechanism: Controlled, monitored exercise and risk-factor management enhance quality of life while respecting DSP limits. AHA Journals

7) Psychological support — Description: Counseling for fear of shocks, genetic guilt, body-image concerns from skin disease. Purpose: Reduce anxiety/depression that worsen symptom perception. Mechanism: Cognitive-behavioral tools and peer support improve adherence and resilience in inherited heart disease. AHA Journals

8) Skin care regimen (emollients + keratolytics) — Description: Daily urea or salicylic acid creams, emollients, and careful paring of thick skin; treat fissures early. Purpose: Reduce pain, infection, and disability from keratoderma. Mechanism: Keratolytics thin the thick stratum corneum; emollients seal moisture and restore barrier function. Medical Journals

9) Podiatry and footwear optimization — Description: Insoles, off-loading pads, and roomy shoes to reduce pressure. Purpose: Prevent fissures and infections. Mechanism: Pressure redistribution lowers mechanical trauma on hyperkeratotic skin. Medical Journals

10) Workplace and heat-exposure adjustments — Description: Limit heavy manual labor, hot environments, and dehydration. Purpose: Reduce arrhythmia triggers and skin cracking. Mechanism: Less thermal/mechanical stress on heart and skin. heart.bmj.com

11) Family screening protocol — Description: Schedule ECG/echo or CMR for first-degree relatives at intervals. Purpose: Catch silent disease early. Mechanism: Early CMR detects scar before symptoms; counseling tailors sports/ICD decisions. PMC

12) Vaccination and infection-prevention — Description: Up-to-date flu/COVID and routine vaccines; prompt care for cellulitis in fissures. Purpose: Avoid fever-triggered hot-phases and decompensation. Mechanism: Preventing systemic inflammation reduces arrhythmia and HF flares. AHA Journals

13) Sleep and rhythm hygiene — Description: Treat sleep apnea; regular sleep schedule; limit stimulants. Purpose: Lower sympathetic surges and ectopy. Mechanism: Better autonomic balance reduces ventricular triggers. AHA Journals

14) Salt-smart nutrition & fluid routines — Description: Heart-failure-style salt awareness; dietitian review. Purpose: Control fluid buildup. Mechanism: Less sodium reduces edema and dyspnea. AHA Journals

15) Avoid QT-/proarrhythmic drugs — Description: Pharmacist review before new meds. Purpose: Prevent drug-induced arrhythmias on top of DSP substrate. Mechanism: Avoids additive conduction risks. AHA Journals

16) Sun and friction protection for skin — Description: Socks/gloves, lubricants, and rest breaks for hands/feet. Purpose: Cut fissure risk. Mechanism: Reduces shear stress on hyperkeratotic areas. Medical Journals

17) Pregnancy planning — Description: Pre-pregnancy cardiology/genetics consult; close monitoring if pregnant. Purpose: Manage hemodynamic stress and rhythm risk. Mechanism: Team-based surveillance and medication safety guidance. heartrhythmjournal.com

18) Fall/syncope safety planning — Description: Home safety changes if you have frequent blackouts. Purpose: Prevent injury while definitive therapy is arranged. Mechanism: Reduces harm from VT-related syncope. AHA Journals

19) Telemonitoring and early review of wearables — Description: Share device alerts and rhythm strips with the clinic. Purpose: Rapid response to new arrhythmias. Mechanism: Detects trend changes before big events. AHA Journals

20) Education for schools/employers — Description: Provide a brief letter about the condition, limits, and emergency steps. Purpose: Safer participation and reduced stigma. Mechanism: Awareness improves support and timely help. PMC

---

Drug treatments

(Each includes class, common dosing examples for adults unless noted, timing, purpose, mechanism, key side effects. Doses are general references—people must follow their own doctor’s orders.)

1) Beta-blockers (e.g., metoprolol, bisoprolol, nadolol) — Class: antiadrenergic. Dose: metoprolol succinate 25–200 mg daily. Purpose: reduce palpitations and shocks. Mechanism: blunts adrenaline effects, lowering ventricular ectopy/VT. Side effects: fatigue, low BP, slow pulse, depression, sexual dysfunction. AHA Journals

2) Sotalol — Class: class III antiarrhythmic + beta-blocker. Dose: 80–160 mg twice daily (renal-adjust). Purpose: suppress VT and reduce ICD therapies. Mechanism: prolongs action potential and blocks beta receptors. Side effects: torsades (QT prolongation), bradycardia, fatigue—needs ECG/QT monitoring. AHA Journals

3) Amiodarone — Class: class III antiarrhythmic (broad). Dose: load 800–1200 mg/day → 200 mg/day maintenance. Purpose: suppress recurrent VT when others fail. Mechanism: multiple channel blockade. Side effects: thyroid, liver, lung toxicity; eye/skin changes; many drug interactions. AHA Journals

4) ACE inhibitors (e.g., enalapril, lisinopril) — Class: neurohormonal blocker. Dose: enalapril 2.5–20 mg bid. Purpose: treat LV dilation/HF, improve outcomes. Mechanism: RAAS blockade reduces remodeling. Side effects: cough, high potassium, kidney effects, angioedema (rare). AHA Journals

5) ARBs (e.g., losartan, valsartan) — Class: RAAS blocker. Dose: losartan 25–100 mg daily. Purpose: alternative to ACEI for intolerance. Mechanism: blocks angiotensin II receptor. Side effects: high potassium, dizziness, kidney effects. AHA Journals

6) ARNI (sacubitril/valsartan) — Class: neprilysin inhibitor + ARB. Dose: 24/26–97/103 mg bid. Purpose: for HFrEF to reduce hospitalizations/death. Mechanism: augments natriuretic peptides + RAAS block. Side effects: hypotension, hyperkalemia, cough, rare angioedema. AHA Journals

7) Mineralocorticoid receptor antagonists (spironolactone/eplerenone) — Class: aldosterone blocker. Dose: spironolactone 12.5–50 mg daily. Purpose: HF benefit, antifibrotic effect. Mechanism: reduces remodeling and potassium loss. Side effects: high potassium, gynecomastia (spironolactone). AHA Journals

8) Loop diuretics (furosemide, torsemide) — Class: diuretic. Dose: furosemide 20–80 mg/day (variable). Purpose: relieve fluid overload. Mechanism: increases urine sodium/water. Side effects: dehydration, low potassium/magnesium, dizziness. AHA Journals

9) SGLT2 inhibitors (dapagliflozin, empagliflozin) — Class: cardiometabolic. Dose: 10 mg daily. Purpose: HFrEF benefit regardless of diabetes. Mechanism: natriuresis, improved energetics/inflammation. Side effects: genital infections, volume depletion. AHA Journals

10) Ivabradine — Class: If-channel blocker. Dose: 5–7.5 mg bid. Purpose: HF symptom control if HR≥70 on beta-blocker. Mechanism: slows sinus node without lowering BP. Side effects: luminous phenomena, bradycardia. AHA Journals

11) Anti-infectives for skin fissures (topical/short oral courses) — Class: antibiotics/antiseptics as indicated. Purpose: treat secondary infections from keratoderma cracks. Mechanism: reduce bacterial load and cellulitis risk. Side effects: drug-specific; use as prescribed. Medical Journals

12) Topical keratolytics (urea 20–40%, salicylic acid 6–12%) — Class: dermatologic. Dose: nightly to thick skin; protect surrounding normal skin. Purpose: soften keratoderma and heal fissures. Mechanism: breaks down excess keratin. Side effects: local irritation; avoid on open deep wounds. Medical Journals

13) Topical retinoids / systemic acitretin (specialist use) — Class: vitamin A derivatives. Dose: acitretin e.g., 10–25 mg/day (dermatologist-directed). Purpose: severe keratoderma unresponsive to basics. Mechanism: normalizes keratinization. Side effects: teratogenicity (strict precautions), dry lips/skin, liver effects. Medical Journals

14) Potassium and magnesium repletion (when low) — Class: electrolyte therapy. Dose: individualized. Purpose: reduce ventricular ectopy when depleted. Mechanism: stabilizes myocardial conduction. Side effects: GI upset; avoid over-replacement. AHA Journals

15) Anticoagulation (selected cases) — Class: DOAC/warfarin. Dose: per guideline. Purpose: prevent thromboembolism with severe LV dysfunction or atrial fibrillation. Mechanism: reduces clot formation. Side effects: bleeding. AHA Journals

16) Digoxin (selected) — Class: inotrope. Dose: 0.125–0.25 mg/day (renal-adjust). Purpose: symptom relief in AF with low BP limiting beta-blockers. Mechanism: increases vagal tone and contractility. Side effects: arrhythmias, toxicity with low K/Mg. AHA Journals

17) ACEI/ARB for relatives with early changes — Class: preventive remodeling therapy (expert opinion). Dose: low, titrate. Purpose: slow structural change in early LV involvement. Mechanism: antifibrotic/antiremodeling. Side effects: as above. AHA Journals

18) Colchicine/NSAIDs (short course for hot-phase pericarditis-like pain; specialist) — Class: anti-inflammatory. Dose: colchicine 0.5–0.6 mg bid short term. Purpose: symptom relief in inflammatory flares. Mechanism: NLRP3 and microtubule modulation. Side effects: GI upset; drug interactions. AHA Journals

19) Guideline-directed HF bundle (4 pillars together) — Class: ACEI/ARB/ARNI + beta-blocker + MRA + SGLT2i. Purpose: best HF outcomes. Mechanism: multi-pathway remodeling control. Side effects: as above; requires lab monitoring. AHA Journals

20) Short-term antiarrhythmic infusion (hospital) — Class: IV amiodarone/lidocaine for unstable VT. Purpose: acute rhythm control before ablation/ICD programming. Mechanism: membrane-stabilizing and multi-channel effects. Side effects: hypotension, bradycardia; monitored in hospital. AHA Journals

---

Dietary “molecular supplement” items

Important: No supplement reverses DSP mutations. These are adjuncts for general heart health if your clinician agrees.

1. Omega-3 fatty acids (fish oil): modest antiarrhythmic/anti-inflammatory effects; typical 1 g/day EPA/DHA; watch bleeding risk on anticoagulants. 2) Coenzyme Q10: may help HF symptoms/quality of life (100–200 mg/day); mechanism: mitochondrial support. 3) Vitamin D (replete deficiency to guideline targets): immune and muscle health. 4) Magnesium (only if low): stabilizes rhythm; dose individualized. 5) Potassium-rich foods (if not hyperkalemic): conduction stability. 6) Taurine (conditional, limited evidence): membrane stabilization/osmotic effects. 7) Thiamine (B1) repletion in diuretic users/low intake. 8) L-carnitine (conditional): fatty-acid transport in myocardium. 9) Probiotics (general GI/immune support if tolerated). 10) Zinc (deficiency correction for skin healing). Always clear supplements with your cardiologist to avoid interactions (e.g., with amiodarone/warfarin). AHA Journals

---

Immunity-booster / regenerative / stem-cell” drugs

There is no proven immune-booster or stem-cell drug that fixes desmoplakin defects in humans. Below are research or supportive concepts used in heart failure broadly; they are not established therapies for Carvajal, and dosing must be specialist-led.

1. Standard HF neurohormonal blockers (ARNI, ACEI/ARB, MRA, SGLT2i) — reduce inflammation/remodeling (disease-modifying for HF, not gene repair). 2) Colchicine (selected hot-phases) — anti-inflammatory signal dampening. 3) Cardiac cell therapy (investigational) — mixed trial results; not standard of care. 4) Gene therapy (preclinical for desmosomal proteins) — concept under study, no approved DSP therapy. 5) Anti-fibrotic agents (research) — TGF-β pathway targets are investigational. 6) mRNA/protein replacement (theoretical) — future direction. Patients should avoid unregulated “stem-cell” clinics. AHA Journals+1

---

Procedures/surgeries

1. ICD implantation — Procedure: a small device under the skin with a lead to the heart. Why: prevents sudden death by stopping VT/VF in high-risk DSP patients. AHA Journals

2. Catheter ablation of VT — Procedure: mapping and cauterizing scar pathways with a catheter. Why: reduce recurrent VT/ICD shocks when meds fail. AHA Journals

3. Cardiac resynchronization therapy (CRT) / physiologic pacing — Procedure: specialized pacing to re-coordinate heartbeats when conduction is delayed. Why: improve HF symptoms and function in selected patients. HRS

4. LV assist device (LVAD) — Procedure: implantable pump supporting blood flow. Why: bridge to transplant or destination therapy in advanced HF. AHA Journals

5. Heart transplantation — Procedure: replacing the failing heart with a donor heart. Why: definitive therapy for end-stage, refractory disease. AHA Journals

---

Prevention tips

1. Confirm diagnosis with genetic testing and follow a screening plan.

2. Avoid endurance sports; choose gentle activity.

3. Take prescribed meds regularly.

4. Keep electrolytes and thyroid normal.

5. Vaccinate and treat fevers/infections early.

6. 6) Limit alcohol; avoid stimulants and QT-prolonging drugs unless essential.

7. Manage heat and dehydration.

8. Protect palms/soles to prevent fissures/infections.

9. Share an emergency plan with family/work/school.

10. Regular follow-up with a center experienced in inherited cardiomyopathies. AHA Journals+1

---

When to see a doctor

• Go to emergency now for fainting, severe chest pain, sustained fast heartbeat, or sudden breathlessness. These can be ventricular arrhythmias or hot-phase myocardial injury.

• Urgent appointment if you notice new palpitations, swelling, weight gain >2 kg in 3 days, or painful infected skin fissures.

• Routine follow-up every 6–12 months (or as advised) with ECG/Holter, labs, and periodic CMR to track scar. AHA Journals+1

---

What to eat & what to avoid

1. Eat: vegetables, fruits, legumes, whole grains, fish (omega-3s), olive oil—Mediterranean-style.

2. Limit sodium (HF-style guidance).

3. Stay hydrated sensibly (ask about fluid limits).

4. Adequate protein to maintain muscle.

5. Correct deficiencies (vitamin D, magnesium, potassium only if low).

6. Avoid: energy drinks/stimulants, binge alcohol, high-salt ultra-processed foods.

7. Be careful with grapefruit if taking amiodarone.

8. Moderate caffeine; avoid if it triggers palpitations.

9. Keep weight steady.

10. Discuss supplements with your cardiologist to prevent interactions. AHA Journals

---

FAQs

1. Is Carvajal syndrome the same as Naxos disease? No. Both are cardio-cutaneous, but Naxos is usually plakoglobin; Carvajal is desmoplakin and often left-dominant heart disease. PMC+1

2. How is it inherited? Classic Carvajal is often autosomal recessive; some DSP cardiomyopathies are autosomal dominant. Family testing is important. PMC+1

3. Can you have heart disease without skin signs? Yes—DSP-CM can present with little/no skin disease. PMC

4. Why do athletes with DSP do worse? Endurance stress promotes scar and arrhythmias. heart.bmj.com

5. What does the MRI show? Subepicardial LGE scar, often ring-like in the LV; it predicts arrhythmic risk. PMC

6. What is a “hot-phase” episode? Sudden chest pain and high troponin mimicking myocarditis; common in DSP. PMC

7. Is there a cure? No gene repair yet; management prevents events and treats HF. PMC+1

8. Do I need an ICD? A team decides using symptoms, scar, VT history, and guidelines. AHA Journals

9. Can ablation replace an ICD? No. Ablation may reduce VT, but ICD is the safety net. AHA Journals

10. Are retinoids safe for skin? They help severe keratoderma but require specialist oversight (e.g., teratogenic). Medical Journals

11. Should my children be tested? Yes—counseling + genetic/ECG/CMR as advised. PMC

12. Can pregnancy be safe? Many do well with close monitoring and tailored meds. heartrhythmjournal.com

13. What about supplements? Supportive only; avoid interactions; ask your clinician. AHA Journals

14. Is DSP cardiomyopathy common in kids? It exists; pediatric series describe left-dominant scar and hot-phases. AHA Journals

15. Where can clinicians find criteria? See 2023–2024 ACM consensus/guidelines for diagnosis and risk tools. PMC+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 23, 2025.